Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
17 juil. 2024 16h14 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
United States Ophthalmology KOLs Fair-Market Value Compensation Rates Report: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs)
10 juil. 2024 04h24 HE
|
Research and Markets
Dublin, July 10, 2024 (GLOBE NEWSWIRE) -- The "Fair-Market Value Compensation Rates for Ophthalmology KOLs - United States" report has been added to ResearchAndMarkets.com's offering. Thought...
Long-time collaborators Botond Roska and José-Alain Sahel win the Wolf Prize 2024 in the field of medicine
05 juil. 2024 03h00 HE
|
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
Botond Roska and José-Alain Sahel have been awarded the Wolf Prize in Medicine for their pioneering work on restoring vision to blind patients using optogenetic therapy. The Wolf...
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
28 juin 2024 16h04 HE
|
NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
27 juin 2024 08h49 HE
|
Spherix Global Insights
Exton, Pennsylvania, June 27, 2024 (GLOBE NEWSWIRE) -- Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in blindness. That...
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
24 juin 2024 09h27 HE
|
Spherix Global Insights
EXTON, PA., June 20, 2024, June 24, 2024 (GLOBE NEWSWIRE) -- The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly...
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
21 juin 2024 07h00 HE
|
Ocugen
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) --...
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
20 juin 2024 06h30 HE
|
Ocugen
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
12 juin 2024 07h05 HE
|
Clearside Biomedical, Inc.
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ...
Verana Health Announces Launch of Qdata® Uveitic Macular Edema Module
30 mai 2024 09h00 HE
|
Verana Health, Inc.
Expansive, high-quality real-world dataset of more than 152,000 de-identified patients utilizes electronic health record data to confirm the diagnosis and better understand the outcomes of patients...